Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of anti-IL-4Rα monoclonal antibody 611 in pediatric and adolescent patients with moderate-to-severe atopic dermatitis
CTR20240903Phase 2Completed
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SSGJ-611 in atopic dermatitis (AD), sponsored by 3S Guojian Pharmaceutical. Started Jul 2024; status: completed.
02
Drugs
SSGJ-611
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20240903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240903.